Gyre Therapeutics (Gyre Therapeutics) Days Payable : 18.78 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Days Payable?

Gyre Therapeutics's average Accounts Payable for the six months ended in Dec. 2023 was $0.2 Mil. Gyre Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2023 was $4.6 Mil. Hence, Gyre Therapeutics's Days Payable for the six months ended in Dec. 2023 was 9.39.

The historical rank and industry rank for Gyre Therapeutics's Days Payable or its related term are showing as below:

GYRE' s Days Payable Range Over the Past 10 Years
Min: 14.2 Med: 18.78 Max: 22.78
Current: 18.78

During the past 3 years, Gyre Therapeutics's highest Days Payable was 22.78. The lowest was 14.20. And the median was 18.78.

GYRE's Days Payable is ranked worse than
91.38% of 719 companies
in the Biotechnology industry
Industry Median: 147.29 vs GYRE: 18.78

Gyre Therapeutics's Days Payable declined from Dec. 2021 (22.78) to Dec. 2023 (18.78). It may suggest that Gyre Therapeutics accelerated paying its suppliers.

Gyre Therapeutics Days Payable Historical Data

The historical data trend for Gyre Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Days Payable Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

22.78

14.20

18.78

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
Days Payable	22.78	14.20	18.78

Competitive Comparison of Gyre Therapeutics's Days Payable

For the Biotechnology subindustry, Gyre Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Days Payable falls into.

Gyre Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Gyre Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.122	+	0.355)	/	2 )	/	4.636	*	365
=	0.2385					/	4.636	*	365
=	18.78

Gyre Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.122	+	0.355)	/	2 )	/	4.636	*	365 / 2
=	0.2385					/	4.636	*	365 / 2
=	9.39

Gyre Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023